The Aussie biotech betting on life after Ozempic
Former pharma executive Karinza Phoenix is raising $5 million and preparing an ASX listing as Myopharm advances a diabetes drug it hopes can complement the GLP-1 giants. Karinza Phoenix hasn’t found it hard raising the $6 million that’s got her biotech firm, Myopharm, onto the fast-track approval process for its Type 2 diabetes drug. “How […]